Lineage, Inc. Common Stock (LINE)vsSabra Healthcare REIT Inc (SBRA)
LINE
Lineage, Inc. Common Stock
$42.63
-1.32%
REAL ESTATE · Cap: $11.14B
SBRA
Sabra Healthcare REIT Inc
$18.46
+4.47%
REAL ESTATE · Cap: $4.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 557% more annual revenue ($5.36B vs $815.66M). SBRA leads profitability with a 19.2% profit margin vs -2.7%. SBRA earns a higher WallStSmart Score of 59/100 (C).
LINE
Avoid34
out of 100
Grade: F
SBRA
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
+84.2%
Fair Value
$124.38
Current Price
$18.46
$105.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 31.4%
Reasonable price relative to book value
Revenue surging 21.7% year-over-year
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Moderate valuation
ROE of 5.6% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SBRA
The strongest argument for SBRA centers on Operating Margin, Price/Book, Revenue Growth. Profitability is solid with margins at 19.2% and operating margin at 31.4%. Revenue growth of 21.7% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SBRA
The primary concerns for SBRA are P/E Ratio, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SBRA is a growth play — different risk/reward profiles.
SBRA is growing revenue faster at 21.7% — sustainability is the question.
SBRA generates stronger free cash flow (98M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SBRA scores higher overall (59/100 vs 34/100), backed by strong 19.2% margins and 21.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Visit Website →Sabra Healthcare REIT Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 skilled nursing / transitional care facilities, (ii) 64 senior housing communities (?
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?